The Effectiveness of Cardiac Resynchronization Therapy in Non-ambulatory NYHA Class IV Patients

Seong Soo Lee
Youngjun Park
Hee-jin Kwon
June Soo Kim
Young Keun On
Kyoung-Min Park
Seung-Jung Park

**Introduction**: The effectiveness of cardiac resynchronization therapy (CRT) in non-ambulatory NYHA class IV (Nam-IV) patients are not well established. We evaluated the role of CRT as an treatment option for Nam-IV patients in terms of clinical, electrocardiographic and echocardiographic improvement.

**Methods**: From October 2005 to December 2017, a total of 159 patients had undergone de novo CRT implantation at our institute. Nam-IV was defined as following criteria : (1) resting dyspnea, (2) dependent on intravenous (IV) inotropes, vasopressors, diuretics, or vasodilators and/or mechanical support, (3) at least one episode of tapering failure of IV drugs or weaning failure of mechanical supports, and (4) non-elective CRT procedure. According to the criteria, 17 were classified as Nam-IV patients. We evaluated the effectiveness of CRT in terms of survival rate, symptom improvement, duration of IV drug use, annual rehospitalization, electrocardiographic and echocardiographic parameters.

**Result**: Baseline characteristics and change of clinical parameters are shown in Table 1 and Table 2. During the index hospitalization, 3 patients were died due to heart failure (HF) progression. Among 14 survivors, 12 patients showed symptom improvement to NYHA class II and 2 patients to NYHA class III before discharge and significant reduction of duration of IV drug use before and after the procedure (10.4±6.9 days vs 5.2±5.3 days, p=0.037). There was marked improvement of QRS duration (166.1±29.0 msec vs 151.9±20.5 msec, p=0.01). Only 1 patient undergone heart transplantation at 3 months after CRT implantation. The number of annual hospitalization associated with HF aggravation was significantly reduced before and after CRT implantation among 13 survivors at 12 months (1.9±1.6 vs 0.3±0.6, p=0.002). Although there was no significant reduction of LV chamber size, LV ejection fraction was markedly improved at 12 months (20.6±6.7% vs 29.3±13.2%, p=0.029).

**Conclusion**: CRT could be considered as a treatment option for Nam-IV patients. The effectiveness of CRT in such severely ill patients group was observed in acute phase and also through 12 months after CRT implantation.